Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
MARCH 24, 2023
The selections feature topics ranging from an analysis of the approval and marketing of biosimilars with a skinny label and their associated Medicare savings, to a discussion of the Philips Respironics recall and the need for reforms to U.S. Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D. 2023 Feb 23.
Let's personalize your content